📰 Full Story
Top Natera Inc. (NASDAQ: NTRA) executives and senior managers disclosed a series of large stock sales on Feb. 2-3, 2026.
CEO Steven L. Chapman sold tens of thousands of shares in multiple transactions — MarketBeat reported 85,299 shares for about $19.7 million (Investing.com reported a slightly higher figure) — reducing his direct holdings by roughly 40%. CFO Michael Brophy sold 6,939 shares for about $1.58 million, and Solomon Moshkevich, president of clinical diagnostics, sold about 4,639 shares for roughly $1.07 million; other smaller insider disposals were also filed.
Several sales were executed under pre-arranged Rule 10b5-1 plans and some to cover taxes on vested RSUs.
The disclosures coincided with a sharp one-day market move — NTRA shares fell about $22 (near a 9.7% decline) to roughly $205.61 — against a backdrop of strong preliminary fourth-quarter results (nearly 40% revenue growth year-over-year), an FDA premarket approval submission for the Signatera CDx test, completed enrollment in a transplantation study and new AI initiatives.
Natera’s market capitalization is roughly $28.4 billion and institutional ownership is high.





)












💬 Commentary